Venetoclax plus azacitidine (Ven/Aza) demonstrates promising efficacy and safety in younger adults with non-favorable-risk AML regardless of fitness for intensive chemotherapy (IC).
Meta-analyses indicate high remission rates, measurable residual disease (MRD) negativity, and substantial rates of hematopoietic stem cell transplantation (HSCT) after Ven/Aza in this population.
Direct randomized comparisons show Ven/Aza achieves superior event-free survival and lower toxicity versus traditional induction chemotherapy in fit younger AML patients, challenging existing treatment paradigms.
While combination triplet regimens involving FLT3 inhibitors show promising remission depth in specific subgroups, randomized validation against Ven/Aza doublets remains necessary.
